Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
5.54
-0.21 (-3.61%)
May 9, 2025, 9:53 AM - Market open

Serina Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.050.063.150.593.46
Revenue Growth (YoY)
-98.37%-98.22%433.05%-82.93%-
Cost of Revenue
7.487.482.391.573.8
Gross Profit
-7.43-7.420.77-0.98-0.33
Selling, General & Admin
9.848.152.31.291.3
Operating Expenses
11.688.152.31.291.3
Operating Income
-19.11-15.57-1.53-2.27-1.63
Interest Expense
-0.34-0.53-0.56-0.02-0
Interest & Investment Income
---00.01
Other Non Operating Income (Expenses)
19.9113.381.36-0.120.21
EBT Excluding Unusual Items
0.46-2.71-0.73-2.41-1.42
Merger & Restructuring Charges
-1.48-1.48-1.6--
Gain (Loss) on Sale of Investments
----0.01-0.01
Gain (Loss) on Sale of Assets
-----0.03
Other Unusual Items
--7.027.6-0.270.19
Pretax Income
-1.01-11.215.27-2.68-1.26
Earnings From Continuing Operations
-1.01-11.215.27-2.68-1.26
Minority Interest in Earnings
0.080.07---
Net Income
-0.94-11.145.27-2.68-1.26
Net Income to Common
-0.94-11.145.27-2.68-1.26
Shares Outstanding (Basic)
97222
Shares Outstanding (Diluted)
97722
Shares Change (YoY)
280.66%0.11%242.70%0.01%-
EPS (Basic)
-0.10-1.512.36-1.25-0.59
EPS (Diluted)
-0.10-1.510.72-1.25-0.59
Free Cash Flow
-19.89-17.16-2.98-2.09-2.34
Free Cash Flow Per Share
-2.19-2.33-0.41-0.97-1.09
Gross Margin
--24.26%-165.95%-9.63%
Operating Margin
-37468.63%-27807.14%-48.52%-383.83%-47.09%
Profit Margin
-1841.18%-19894.64%167.11%-453.44%-36.50%
Free Cash Flow Margin
-39000.00%-30641.07%-94.51%-352.55%-67.41%
EBITDA
-18.92-15.38-1.44-2.21-1.6
EBITDA Margin
---45.67%--46.13%
D&A For EBITDA
0.190.190.090.060.03
EBIT
-19.11-15.57-1.53-2.27-1.63
EBIT Margin
---48.52%--47.09%
Revenue as Reported
0.050.063.150.593.46
Updated Mar 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q